MedPage Today -- Rivaroxaban, an investigative oral factor Xa inhibitor, appears to reduce the risk of deep vein thrombosis by 50% among hip and knee replacement patients when compared with enoxaparin (Lovenox), researchers reported here.
MedPage Today -- Rivaroxaban, an investigative oral factor Xa inhibitor, appears to reduce the risk of deep vein thrombosis by 50% among hip and knee replacement patients when compared with enoxaparin (Lovenox), researchers reported here.